Abstract
In the past few years there has been an increasing appreciation of the importance of Toll-like receptors (TLRs), not just in immunity, but also in autoimmune diseases. TLRs were first identified as sensors of viral and bacterial pathogens that form an integral part of the innate immune response. It was later discovered that these receptors can also respond to endogenous ligands that are produced as a result of tissue damage. This leads to the hypothesis that TLRs may be key contributors to the pathogenesis of chronic inflammatory conditions. A large body of data supporting the role of TLRs in autoimmunity has emerged from animal models and more data is increasingly being generated from human studies as further tools to examine these receptors have become available. Developing strategies to manipulate TLR function is of great interest in autoimmunity, as well as other diseases that include allergy and cancer. This review explores the evidence that points to a role for TLRs in autoimmunity and highlights some of the potential ways in which modulation of their action may yield clinical benefits.
Keywords: Toll-like receptors, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, antagonist, therapies
Current Drug Targets
Title: Targeting Toll-like Receptors in Autoimmunity
Volume: 10 Issue: 11
Author(s): K. S. Midwood, A. M. Piccinini and S. Sacre
Affiliation:
Keywords: Toll-like receptors, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, antagonist, therapies
Abstract: In the past few years there has been an increasing appreciation of the importance of Toll-like receptors (TLRs), not just in immunity, but also in autoimmune diseases. TLRs were first identified as sensors of viral and bacterial pathogens that form an integral part of the innate immune response. It was later discovered that these receptors can also respond to endogenous ligands that are produced as a result of tissue damage. This leads to the hypothesis that TLRs may be key contributors to the pathogenesis of chronic inflammatory conditions. A large body of data supporting the role of TLRs in autoimmunity has emerged from animal models and more data is increasingly being generated from human studies as further tools to examine these receptors have become available. Developing strategies to manipulate TLR function is of great interest in autoimmunity, as well as other diseases that include allergy and cancer. This review explores the evidence that points to a role for TLRs in autoimmunity and highlights some of the potential ways in which modulation of their action may yield clinical benefits.
Export Options
About this article
Cite this article as:
Midwood S. K., Piccinini M. A. and Sacre S., Targeting Toll-like Receptors in Autoimmunity, Current Drug Targets 2009; 10 (11) . https://dx.doi.org/10.2174/138945009789735101
DOI https://dx.doi.org/10.2174/138945009789735101 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Inhibitors of Membrane Receptors Involved with Leukocyte Extravasation
Mini-Reviews in Medicinal Chemistry Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis
Current Pharmaceutical Design Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Food Ingredients and Lipid Mediators
Current Nutrition & Food Science Human Fetal Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Novel Molecular Targets for Systemic Lupus Erythematosus and Other Immune-Complex and T-Cell Mediated Autoimmune Diseases - Update
Medicinal Chemistry Reviews - Online (Discontinued) ‘Toll’ Gates for Future Immunotherapy
Current Pharmaceutical Design Editorial [Hot Topic: Innate Immunity and Autoimmune Disease (Guest Editors: F. Susan Wong and Li Wen)]
Current Molecular Medicine The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Current Drug Targets